Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Elritercept shows durable responses in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence: Updated Results from an ongoing Phase 2 trial

Lynette Chee, Shuhying Tan, David Valcárcel et al. Nov 03, 2025 pp. 787-787 10.1182/blood-2025-787

Abstract Background: Transfusion dependency is associated with substantial burden to patients with transfusion dependent anemia in the setti...

Hemophagocytic lymphohistiocytosis in the community: Real-world evidence and insights from a rare illness in the tertiary university system.

Sumrah Khan, Nehemias Guevara Rodriguez, Brian Abboud et al. Nov 03, 2025 pp. 4759-4759 10.1182/blood-2025-4759

Abstract Background: Hemophagocytic Lymphohistiocytosis (HLH) is an immune hyperactivation disease characterized by widespread multiorgan da...

Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase

Mina Abdelmalek, Farah Al Haj, Fadi Haddad et al. Nov 03, 2025 pp. 2010-2010 10.1182/blood-2025-2010

Abstract Introduction: Chronic myeloid leukemia in myeloid blast phase (CML-MBP) is an aggressive and uncommon clinical entity with limited...

Modifications in risk classification of acute myeloid leukemias undergoing less intensive chemotherapy comparing the 2022 and 2024 stratifications of the european leukemianet and their impact on treatment decision, response rates and outcomes of a brazilian cancer center.

Luciana Magalhães Brandão, Julia Aith Baltazar, Nina Maia Santana et al. Nov 03, 2025 pp. 6943-6943 10.1182/blood-2025-6943

Abstract INTRODUCTION: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with a genetic variability that plays a role i...

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

Jian Huang, Rumeng Li, Tiejun Gong et al. Nov 03, 2025 pp. 5530-5530 10.1182/blood-2025-5530

Abstract Background: OB756 is a novel, orally administered, selective JAK2 inhibitor that targets the JAK–STAT signaling pathway. It has bee...

Cost-conscious CAR T delivery: Outpatient (OP) cilta-cel administration reduces health care resource utilization (HCRU) and the associated post-infusion cost

Christopher Ferreri, Mahmoud Gaballa, Minifrida Santiago et al. Nov 03, 2025 pp. 2634-2634 10.1182/blood-2025-2634

Abstract Introduction: Cilta-cel is a BCMA-targeted CAR T cell therapy approved for the treatment of lenalidomide-refractory multiple myelom...

Reclaiming the clinical social work role: A call for reform in sickle cell disease psychosocial care

Carrianne Stoker-Postier, Allison McGirr-Crowley, Shirley Johnson et al. Nov 03, 2025 pp. 125-125 10.1182/blood-2025-125

Abstract Background:Psychosocial services remain under-integrated and inconsistently supported in comprehensive sickle cell disease (SCD) ca...

A novel kinase-related gene signature predicts the survival and therapeutic responses of Acute Myeloid Leukemia

Haibo Yu, Yingying Huo, Haixiao Zhang et al. Nov 03, 2025 pp. 7011-7011 10.1182/blood-2025-7011

Abstract Background Acute Myeloid Leukemia (AML) is a malignant blood disease with a poor prognosis. Kinase plays an imp...

User experience with pegcetacoplan on-body injector in patients with paroxysmal nocturnal hemoglobinuria

Carlos de Castro, Carl Friddle, Jed Perler et al. Nov 03, 2025 pp. 6728-6728 10.1182/blood-2025-6728

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired condition characterized by complement-mediated hemolysi...

Long-term follow-up of novel post-transplant cyclophosphamide (PTCy) and abatacept (aba) graft-versus-host disease (GVHD) prophylaxis regimen compared to tacrolimus and methotrexate.

Kaitlyn Dykes, Divya Koura, Aaron Goodman et al. Nov 03, 2025 pp. 7799-7799 10.1182/blood-2025-7799

Abstract Introduction: Advances in relapse and GVHD prevention have led to improved effectiveness and safety of allogeneic hematopoietic cel...

Steroid-sparing use of anakinra for secondary hemophagocytic lymphohistiocytosis in sickle cell disease with multiorgan failure – a case report

Erfan Nasirikhaneghah, Sepideh Namdar, Aytaj Mammadzadeh et al. Nov 03, 2025 pp. 6557-6557 10.1182/blood-2025-6557

Abstract Background: Sickle cell disease (SCD) can cause life-threatening multiorgan failure syndrome (MOFS) in the setting of fat embolizat...

Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor

Kayla McHugh, Yuan Huang, Bridget Austin et al. Nov 03, 2025 pp. 1228-1228 10.1182/blood-2025-1228

Abstract Background Idiopathic multicentric Castleman disease (iMCD) is a morbid hematologic disorder defined by lymphadenopathy with a dist...

Impact of acute pain on health care resource utilization and costs in sickle cell disease in the United States

Jing Voon Chen, Mihail Samnaliev, Yi Pan et al. Nov 03, 2025 pp. 7969-7969 10.1182/blood-2025-7969

Abstract Objective: Acute pain is common among patients with sickle cell disease (SCD), but there is limited knowledge of its economic burde...

Platelet transfusion is associated with reduced thrombosis yet elevated mortality in consumptive thrombocytopenias: A retrospective cohort study

Manas Pustake, Lakshmi Kattamuri, Kunal Sharma et al. Nov 03, 2025 pp. 4807-4807 10.1182/blood-2025-4807

Abstract Background: Platelet consumptive disorders (immune thrombocytopenia [ITP], thrombotic thrombocytopenic purpura [TTP], heparin-induc...

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Elan Baskir, Tobias Tix, Mohammad Alhomoud et al. Nov 03, 2025 pp. 3723-3723 10.1182/blood-2025-3723

Abstract Introduction: CAR-T is associated with a spectrum of acute toxicities, including acute cardiovascular events (CVE). The long-term ca...

Analysis of 3346 patients from the combined Children's Oncology Group AML studies further characterizes RAM immunophenotype AML and reveals other associated phenotypes and genetic drivers.

Andrew Menssen, Jacqueline Cook, Todd Alonzo et al. Nov 03, 2025 pp. 337-337 10.1182/blood-2025-337

Abstract Introduction: RAM phenotype acute myeloid leukemia (RAM-AML), identified by flow cytometry at diagnosis, is associated with age und...

Defining therapeutic chimerism thresholds for comprehensive sickle cell disease correction in the townes mouse model

Nicole Mende, Sandra Marbach, Diana Robles Diaz et al. Nov 03, 2025 pp. 4700-4700 10.1182/blood-2025-4700

Abstract Sickle cell disease (SCD) is caused by a point mutation in the beta-globin gene, resulting in the production of an abnormal hemoglo...

Genome-wide association of pica within a cohort of volunteer blood donors implicates the gene encoding neuropeptide VF

Eric Early, Hefei Liu, Bryan Spencer et al. Nov 03, 2025 pp. 2902-2902 10.1182/blood-2025-2902

Abstract Background: Pica is an eating disorder characterized by the persistent craving and consumption of non-food subs...

Enhancing somatic variant oncogenicity assessment – a prospective quality assurance study for rapid and scalable molecular profiling of hematological malignancies

Wenjie Jack Chen, Narasimhan Nagan, Sabrina Gardner et al. Nov 03, 2025 pp. 5165-5165 10.1182/blood-2025-5165

Abstract Next-generation sequencing (NGS) of relevant genes offers critical insights into diagnostic, prognostic, and therapeutic biomarkers...

Pre-malignant extracellular matrix drives leukemia transformation through reprogramming of pre-leukemic stem cells

Alvaro Cuesta-Dominguez, Ioanna Mosialou, Ziwei Chen et al. Nov 03, 2025 pp. 3187-3187 10.1182/blood-2025-3187

Abstract Acute myeloid leukemia (AML) often arises from myelodysplasia (MDS), a pre-leukemic condition characterized by dysplasia and ineffe...

Exploring the disease impact of plasma metabolites on marginal zone lymphoma based on mendelian randomization

Yupiao Feng, Xinting Hu, Yutang Li et al. Nov 03, 2025 pp. 7122-7122 10.1182/blood-2025-7122

Abstract Background: It is reported that altered plasma metabolite levels are associated with disease progression in marginal zone lymphoma...

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

Vanthana Bharathi, Alexandre Bazinet, Alex Bataller et al. Nov 03, 2025 pp. 3405-3405 10.1182/blood-2025-3405

Abstract Background: Acute megakaryoblastic leukemia (AMKL, AML-M7) is a rare, biologically heterogeneous subset of Acute Myeloid Leukemia (...

Evaluating the clinical outcomes of GLP-1 receptor agonists in untreated indolent non-Hodgkin's lymphomas undergoing active surveillance

Patrick Willard, Esteban Toro Velez, Carolina Velez-Mejia et al. Nov 03, 2025 pp. 5385-5385 10.1182/blood-2025-5385

Abstract Background: In asymptomatic indolent non-Hodgkin lymphomas (iNHL) including follicular lymphoma (FL), mantle ce...

Efficacy and prognosis of venetoclax combined with the 3+7 regimen in fit AML: A propensity score-matched cohort study

Boyue Zheng, Jiyi Fu, Jun Wang et al. Nov 03, 2025 pp. 3463-3463 10.1182/blood-2025-3463

Abstract Objective: To compare the efficacy and survival outcomes between the standard “3+7” regimen and the “3+7” regimen combined with ven...

Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study

Pengpeng Xu, Huilai Zhang, Ping Li et al. Nov 03, 2025 pp. 6293-6293 10.1182/blood-2025-6293

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Polatuzumab vedotin (Pola) ha...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page